After recently tying up a nearly $7 billion deal with Japan’s Daiichi Sankyo for a next-gen breast cancer program, AstraZeneca is happy, for the most part, to focus on its own pipeline and not go after deals.
Speaking to reporters during its second-quarter financials call this morning, the U.K.-based Big Pharma’s CEO Pascal Soriot said: “Our focus is on our pipeline and delivering on our planned growth, improving our operating margin and our cash flow. That is our absolute focus today.”
But, and it was ever thus, Soriot said the company “would remain open to opportunities that come our way” if they are at the “right price” and can add value, like he sees with the Daiichi deal.
He did add, however, that there are “not so many opportunities” for M&A, a common theme among Big Pharma CEOs, who typically bemoan the high prices at which many biotechs are being valued.
AstraZeneca was up 4% in early trading this morning, with sales growing (PDF) at a strong 17% (at constant exchange rates) for the first half, boosted by revenue coming in from new meds as well as a strong showing in China.
By Ben Adams
Source: Fierce Biotech
The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.
It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.
The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.
